Pharmafile Logo
Pharmafocus logo
Advanced Search
galderma

Galderma wins FDA approval for new retinoid molecule acne treatment AKLIEF

October 7, 2019
Sales and Marketing

Galderma, a global leader in skin health, has announced that the FDA has approved the First New Retinoid Molecule for …

News
jj_sign_on_wall

Johnson & Johnson commits $500m to end HIV and TB Epidemics

October 4, 2019
Medical Communications, Research and Development

Johnson & Johnson have announced it has committed to ensuring more than $500 million is dedicated to R&D delivery programs …

News
top_10_photo

Top Ten most popular articles on Pharmafile.com this week

October 4, 2019
Medical Communications

Another week comes to an end at Pharmafile and we run down with the top 10 articles for the week. …

News
shutterstock_212432119

Arbutus Biopharma moves to terminate development of chronic hepatitis B therapy after trial failure

October 4, 2019
Medical Communications, Research and Development Arbutus Biopharma, hepatitis B, pharma

Arbutus Biopharma has announced its decision to terminate the development of its oral capsid inhibitor, known as AB-506, in the …

News
cma-logo-v3

UK watchdog finds drug firms colluded to hike essential NHS medication by 1,800%

October 4, 2019
Medical Communications

The UK’s Competition and Markets Authority (CMA) has provisionally found that three drug firms signed an illegal agreement which led …

News
astrazeneca_building_white

FDA approves single-use auto-injector form of IL-5 inhibitor Fasenra

October 4, 2019
Medical Communications, Sales and Marketing AstraZeneca, FDA, Fasenra, pharma

AstraZeneca is celebrating as the FDA announced the approval of its IL-5 inhibitor Fasenra  (benralizumab) in a pre-filled, single-use auto-injector …

News
gilead-sciences

FDA approves second PrEP drug to prevent HIV infection

October 4, 2019
Medical Communications

The US FDA has approved Gilead’s Descovy (emtricitabine/tenofovir alafenamide) as a second pre-exposure prophylaxis (PrEP) drug in at-risk adults and …

News
servier

Servier gains non-Hodgkin lymphoma drug from CTI BioPharma

October 3, 2019
Medical Communications, Sales and Marketing

French pharma-giant Servier has purchased the medication Pixuvri, indicated for the treatment of non-Hodgkin B-cell lymphoma, from US-based CTI BioPharma. …

News
emma-walmsley-big

GSK Chief Emma Walmsley voices support for equal pay campaign

October 3, 2019
Medical Communications Emma Walmsley, GSK, GlaxoSmithKline, pharma

GlaxoSmithKline Chief Emma Walmsley has joined the chorus of more than a hundred of the UK’s most successful female business …

News
novartis_side_building

Novartis selects Microsoft for AI drug development

October 3, 2019
Research and Development

Novartis has begun an alliance with Microsoft to leverage the latter’s artificial intelligence (AI) technology for the discovery, development and …

News
rocherooflr

NICE rejects Roche’s immunotherapy Tecentriq in unresectable metastatic triple A breast cancer

October 3, 2019
Sales and Marketing Cancer, NICE, Roche, breast cancer, pharma, tecentriq

NICE has revealed its decision not to approve Roche’s immunotherapy Tecentriq (atezolizumab) for use on the NHS in England and …

News
department-of-health-social-care

Government issues first serious shortage protocol to combat lack of the antidepressant fluoxetine

October 3, 2019
Manufacturing and Production

The Department of Health and Social care has brought in measures to allow pharmacists to supply alternative strengths of fluoxetine …

News

Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis

October 3, 2019
Research and Development

Novartis has announced positive data from its PREVENT trial, which evaluated the safety and efficacy of Cosentyx (secukinumab) for patients …

News
sandrock-al-e1548286908776

Biogen announces leadership updates

October 2, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Biogen have announced updates to it senior leadership team with Alfred Sandrock being named Executive Vice President of Research and …

Appointment
opdivo_1_1

BMS’ Opdivo bests chemotherapy in oesophageal squamous cell carcinoma

October 2, 2019
Research and Development Bristol-Myers Squibb, Cancer, ESMO 2019, opdivo, pharma

Bristol-Myers Squibb took the opportunity at the European Society for Medical Oncology (ESMO) 2019 Annual Congress to present new Phase …

News
invokana

FDA grants Johnson & Johnson’s Invokana new kidney disease approval

October 2, 2019
Research and Development

Johnson & Johnson’s Invokana (canaglifolozin) has become the only drug in the SGLT2 inhibitor class to be approved by the …

News

AstraZeneca strikes global commercial rights deal for $243m

October 2, 2019
Research and Development

Cambridge-headquartered AstraZeneca have agreed to sell certain global commercial rights for its Losec brand, in a deal that is worth …

News
gsk_boronia_australia

GSK’s Zejula slows disease progression in a range of ovarian cancers

October 2, 2019
Research and Development Cancer, ESMO 2019, GSK, Zejula, ovarian cancer, pharma

At the 2019 European Society for Medical Oncology (ESMO) congress, GlaxoSmithKline unveiled new Phase 3 data on Zejula (niraparib) for …

News
jj_sign_on_wall

Johnson & Johnson settle opioid lawsuits in Ohio for $20m

October 2, 2019
Research and Development

Johnson & Johnson have agreed to settle opioid litigation with two Ohio counties for roughly $20.4 million in a deal …

News
dave_peacock

MSD announce David Peacock as new Managing Director in UK and Ireland

October 1, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

MSD have announced that David Peacock will become Managing Director in the UK and Ireland, succeeding former director Louise Houson, …

Appointment
The Gateway to Local Adoption Series

Latest content

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026

Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development US

January 29, 2026

Five Facts about spinal muscular atrophy

January 28, 2026